YM Biosciences reports that CIMYM divests nimotuzumab to InnoKeys


YM BioSciences reported that CIMYM BioSciences has sold its assets relating to nimotuzumab to InnoKeys for undisclosed consideration including an immediate $2M payment. CIMYM was a joint venture subsidiary 80% owned by YM BioSciences and 20% owned by CIMAB. CIMAB has reported it has partnered with InnoKeys and they have incorporated a joint venture called InnoMab PTE which is now the owner of the assets related to nimotuzumab.

View Comments (0)